▲ Peaking
Business
Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
Endeavor BioMedicines moves its Hedgehog inhibitor taladegib into Phase III following a successful mid-stage trial win.
Taladegib
1 trends tracked about this subject — the full history, oldest to newest below.